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Abstract
Background: Korea achieved universal health insurance coverage in only 12 years; however,
insufficient government funding has resulted in high out-of-pocket payments and, in turn, a demand
for supplementary private health insurance (PHI). Supplementary PHI provides a fixed amount of
benefits in the event of critical illness (e.g., cancer or stroke), surgery, or hospitalization. In this
study, we tried to identify factors that influence the decision to purchase supplementary PHI and
investigate the impacts of PHI on various aspects of cancer care.
Methods: In a cross-sectional study of 391 patients with gastric cancer, we collected data on
demographic and clinical variables, coverage by PHI at the time of diagnosis, and patients' cancer
care experiences from surgery databases and patient questionnaires. Two separate multivariate
logistic regression models were used 1) to determine whether various sociodemographic and
clinical variables influence the purchase of supplementary PHI, and 2) to determine if there is a
difference in various outcome measures between individuals with and without PHI.
Results: We studied 187 subjects (49.6%) who were covered under PHI at the time of diagnosis.
Subjects who purchased PHI tended to be younger (aOR = 5.01, 95% C.I. = 2.05 – 12.24), and more
educated (aOR = 2.67, 95% C.I. = 1.04 – 6.86). Supplementary PHI coverage was significantly
associated with financial independence (aOR = 2.07, 95% CI = 1.19 – 3.61), but not with other
aspects of cancer care, such as access to healthcare, quality of care, communication and patient
autonomy.
Conclusion: Our findings demonstrate that supplementary PHI neither serves as a safety net for
vulnerable patients nor improves cancer care experience, except for maintaining the financial
independence of beneficiaries.
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Background
Many developing countries, spurred by rapid economic
growth, are faced with increasing public aspirations for
better and affordable health care. For example, when
healthcare topped the list of concerns in China [1], the
Chinese government released a draft of healthcare reform
plans on Oct 14, 2008. These ambitious plans aim to pro-
vide safe, effective, convenient, and affordable basic care
for all citizens by 2020 [2]. When attempting to achieve
universal coverage, the most important question is how to
finance the soaring health care costs. Despite increased
spending, coverage by the Chinese government has
decreased and out-of-pocket payments have risen, imply-
ing that insufficient funds are available [3,4]. In the mean-
time, the demand for private health insurance (PHI) has
become intense and the market, particularly with regards
to supplementary insurance, has dramatically expanded
[5].
South Korea has experienced similar expedited economic
development under an authoritarian political regime and
has achieved universal coverage through the National
Health Insurance (NHI) program in only 12 years. Thus,
South Korea has been the subject of substantial interest
for many developing countries, particularly those with
low and middle incomes [6]. The Korean government
began by introducing mandatory social health insurance
for industrial workers in large corporations in 1977, then
incrementally extended this program to cover self-
employed citizens and eventually the entire population in
1989 [7]. On the other hand, the Korean government has
been unable to control health care costs, and the Korean
NHI is currently experiencing a financial deficit [8,9]. As
the government puts a higher priority on extending the
population coverage, the NHI has maintained a policy of
'low contributions, limited benefits, and high co-pay-
ments'.
The contribution rate in Korea was relatively low as of
2006, with an average of 4.48% of wage income, and the
health insurance benefit package included diagnostic
tests, drugs and medical materials, treatments and surgery,
rehabilitation, and hospitalization. However, many serv-
ices, especially expensive ones, were not covered by the
NHI package. Furthermore, the co-payment rate was uni-
formly 20% for inpatient care, without a ceiling, and 35%
to 50% for hospital outpatient care [6]. These rates lead to
substantial out-of-pocket payments in Korea, accounting
for 37% of the total health care costs in 2004 [10] and
more for serious illnesses (e.g., approximately 50% for
cancer) [11]. Limited coverage and excessive co-payments
have resulted in a relatively low satisfaction rate (i.e.,
47.0%) with the NHI [12] and rapid growth of the PHI
market [13,14]. As the government did not allow for
indemnity plans, most existing PHI plans were disease-
specific products that provide a fixed amount of benefits
in the event of critical illness (e.g., cancer or stroke), sur-
gery, or hospitalization [14].
Recently, there has been intense debate over the govern-
ment's encouragement of PHI in Korea. This controversy
increased when the Korean government proposed a plan
to develop the medical sector as an industry in 2003. Sup-
porters of the plan argue that the private sector is driven
by the need to attract clients, and is therefore in a position
to enhance the efficiency and quality of health care,
increase patient satisfaction, and relieve the financial bur-
den caused by NHI. However, critics of this plan argue
that the potential benefits of PHI have not yet been dem-
onstrated, and the private sector may inadvertently con-
tribute to higher NHI expenditures by spurring patient
demand. Critics are also concerned that PHI could result
in inequities that would further deepen the social dishar-
mony among Koreans and create a sense of incongruity
[6,15]. Thus far, this debate has been waged on theoretical
ideas, rather than on concrete evidence.
Although a limited number of studies have examined the
role of PHI on cancer care in the United States [16,17], the
unique U.S. healthcare system and different socioeco-
nomic background make it difficult to apply the findings
to developing countries. Thus, we sought to identify fac-
tors that influence the decision to purchase supplemen-
tary PHI in Korea, and investigate the impacts of PHI on
various aspects of cancer care, including access to health-
care, quality of care, communication, patient autonomy,
and financial and social independence.
Methods
Study design
We performed a cross-sectional study in 2004 to examine
various aspects of cancer care among gastric cancer
patients. Until recently, gastric cancer was the most com-
monly diagnosed malignancy in Korea, accounting for
20% of new cancer cases in 2002 [18].
Patients were selected from two independent institution-
based stomach surgery databases at the National Cancer
Center and the Samsung Medical Center in Korea. Both
databases have very similar data structures that include
clinical information, such as age at diagnosis, disease
stage, tumor progress, type of surgery (including extent of
lymph node dissection), history of cancer therapy, and
recurrence. Patients who were diagnosed with stage I to
stage III stomach cancer between 2001 and 2002, and
remained disease-free at the time of survey, were regarded
eligible for participation in this study. Patients were
excluded from the study if they had a prior history of other
cancers.BMC Health Services Research 2009, 9:133 http://www.biomedcentral.com/1472-6963/9/133
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Potentially eligible patients were invited to participate in
the study by telephone, and those who agreed to partici-
pate were mailed the questionnaire, consent forms, and a
postage-paid return envelope. Subjects who did not return
the questionnaire within a month received a reminder
card and were telephoned by a research staff member,
who explained the purpose of the study and participation
requirements. Subjects who remained interested were
asked to sign an informed consent form, and complete
and return the questionnaire. Subjects who chose not to
participate were asked to provide reasons. The original
study design and recruitment procedures have been previ-
ously described elsewhere [19]. The study was approved
by the Institutional Review Boards of both medical cent-
ers.
Measurements
We used a questionnaire to collect information on socio-
demographic and clinical characteristics, including vari-
ous aspects of cancer care. Sociodemographic variables
included age, sex, marital status, education level, house-
hold income, residential area, religious status, and
employment status before and after diagnosis. Clinical
data included variables such as comorbidities, smoking
and drinking habits (i.e., before and after diagnosis). Sub-
jects were asked if they were covered by PHI at the time of
diagnosis, and how helpful they found the PHI.
To determine the impacts of PHI, cancer care was assessed
from various perspectives. 'Access to health care' and
'quality of care' were assessed objectively and subjectively.
'Stage at diagnosis' was used as an objective measure to
assess timely access to health care [16], and 'problems
receiving surgery after diagnosis' was assessed subjectively
using a patient questionnaire. 'Guideline compliance' was
used as an objective measure of the quality of care.
Patients were considered to have been treated according
to Korean Gastric Cancer Society (KGCS) guidelines [20]
if they were diagnosed with stage I disease and received
surgery (regardless of chemotherapy) or if they were diag-
nosed with stage II or III disease and received adjuvant
chemotherapy (with or without radiotherapy). We did
not consider the concept of over-treatment, as it was not
relevant to our research questions. 'Overall satisfaction
with care' was used as a subjective measure of the quality
of care. Patient autonomy was assessed by asking subjects
to rate 'the degree of their own involvement in decision
making' and 'the extent that their treatment plans
reflected their own opinions.' 'Payment of treatment costs
by oneself' (i.e., not relying on financial assistance from a
family member or friend) and 'job maintenance after can-
cer treatment' were used to assess financial and social
independence, respectively. Items included in the ques-
tionnaire are described in detail in the Additional file 1.
Statistical analysis
We used a univariate and standard multivariate logistic
regression model to determine whether various sociode-
mographic and clinical variables influenced the purchase
of supplementary PHI in Korea. Results are shown as odds
ratios (OR) and adjusted odds ratios (aOR). A separate
multivariate logistic regression model was used to assess
differences in various outcome measures between persons
with PHI and without PHI. Estimates were adjusted for
possible confounding variables, such as age at diagnosis,
educational status, religion, income, residential area, and
employment status at the time of diagnosis. All statistical
tests were two-sided, and P < 0.05 was considered statisti-
cally significant.
Results
Study participants
Hospital records yielded 855 patients who had undergone
curative surgery for stomach cancer between 2001 and
2002, and we were able to contact 774 patient households
by telephone. However, 83 patients had died and 97
refused to participate in the study because of time con-
straints, inability to communicate verbally or in writing
(i.e., no one was available to help them), or the study was
regarded as an inconvenience or a violation of privacy.
Of the remaining 594 patients, 165 did not return the
questionnaire. Among the remaining 429 patients, 6 were
excluded for not completing the questionnaire and 32
were excluded because they were no longer disease-free.
Thus, 391 study subjects participated in the study (i.e.,
52.8% of the 740 eligible patients).
On average, respondents were 54.5 years old (± 10.6
years). Most respondents were male, diagnosed with stage
I disease, and underwent subtotal gastrectomy. Compared
with patients who did not respond to the questionnaire,
respondents were more likely to be male, younger, and
diagnosed at an earlier stage (Table 1).
Factors associated with the purchase of private health 
insurance
In univariate analyses, patients who were younger (OR =
6.39, 95% C.I. 4.00 – 10.18), more educated (OR = 3.08,
95% C.I. = 2.01 – 4.74), religious (OR = 1.57, 95% C.I. =
1.01 – 2.46), employed at the time of diagnosis (OR =
2.85, 95% C.I = 1.81 – 4.46), earning a higher income
(OR = 3.54, 95% C.I. = 2.22 – 5.64), and living in an
urban area (OR = 2.08, 95% C.I. = 1.27 – 3.40) were more
likely to have supplementary PHI at the time of diagnosis.
Multivariate analysis showed that younger age (aOR =
5.01, 95% C.I. = 2.05 – 12.24) and higher education (aOR
= 2.67, 95% C.I. = 1.04 – 6.86) were independent factors
for having PHI (Table 2).BMC Health Services Research 2009, 9:133 http://www.biomedcentral.com/1472-6963/9/133
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Impacts of private health insurance on cancer care
Among the 187 subjects who were covered by PHI at the
time of diagnosis, nearly all (i.e., 185 subjects) replied
that PHI was very helpful or helpful. Only two people
stated that PHI was not helpful (Table 3).
Access to healthcare services
Having PHI was not significantly associated with earlier
stage of disease at diagnosis (aOR = 1.66, 95% C.I = 0.93
– 2.99) or difficulty receiving surgery (aOR = 1.09, 95%
C.I = 0.59 – 1.74).
Quality of cancer care
Having PHI was not significantly associated with the like-
lihood of receiving treatment according to KGCS guide-
lines (aOR = 2.43, 95% C.I = 0.98 – 6.04). In addition,
PHI was not associated with overall satisfaction with care
(aOR = 1.21, 95% C.I = 0.58 – 2.52).
Communication and patient autonomy
Having PHI was not significantly associated with patient
involvement in the decision-making process (aOR = 0.77,
95% C.I = 0.45 – 1.30) or reflection of the patient's own
opinion in the decision-making process (aOR = 1.03, 95%
C.I = 0.59 – 1.79).
Financial and social independence
Patients with PHI were more likely to pay their own med-
ical bills, rather than depending on family members (OR
= 2.92, 95% C.I. = 1.92 – 4.45). This association remained
significant even after adjusting for potential confounding
variables (aOR = 2.07, 95% CI 1.19 – 3.61) by standard
multiple logistic regression analysis. Among subjects who
were employed at the time of cancer diagnosis (i.e., n =
253), those with PHI were more likely to continue work-
ing after cancer treatment (OR = 1.85, 95% CI = 1.01 –
3.39). However, this association disappeared after multi-
variate adjustment (aOR = 0.93, 95% C.I = 0.43 – 1.99).
Discussion
To our knowledge, this is the first study to examine the
impacts of supplementary PHI on cancer care experienced
by Korean patients. Our findings reveal that older, less-
educated, poorer, and/or unemployed people with cancer
are least likely to be covered by PHI. This raises many con-
cerns with regards to inequity, as these groups of people
are generally more vulnerable to severe financial burdens
when they are affected by serious illnesses such as cancer.
These subjects may elect not to purchase PHI because they
cannot afford it. Alternatively, these subjects may have
been excluded from PHI. In the absence of a well-
equipped underwriting system, premiums are usually
determined by age and gender, and payments are fixed
regardless of the actual medical bills. Thus, there is no
financial incentive for the PHI companies to promote PHI
to high-risk populations. Indeed, nearly all patients who
are over 60 years of age or have pre-existing conditions are
excluded from PHI coverage to avoid adverse selections.
Table 1: Characteristics of responders and non-responders.
Responders
(N = 391)
No (%)*
Non-Responders
(N = 349)
No (%)*
p
Age (years) 54.5 (± 10.6) 57.0 (± 11.6) < 0.01
Sex < 0.01
Male 285 (72.9) 216 (61.9)
Female 106 (27.1) 133 (38.1)
Time since operation (months) 27.5 (± 3.4) 27.6 (± 3.2) NS
Stage < 0.01
Ia 201 (51.7) 162 (46.6)
Ib 76 (19.5) 58 (16.7)
II 73 (18.8) 59 (17.0)
IIIa 30 (7.7) 51 (14.7)
IIIb 9 (2.3) 18 (5.2)
Tumor progress NS
Early 233 (59.6) 158 (40.4)
Advanced 158 (40.4) 169 (48.4)
Operation NS
Subtotal gastrectomy 306 (78.3) 268 (78.6)
Total gastrectomy 85 (21.7) 74 (21.4)
Dissection NS
D1 8 (2.1) 8 (2.3)
D2 378 (96.7) 336 (96.3)
Others 5 (1.3) 5 (1.4)
Abbreviations: NS, not significant; D1, limited lymphadenectomy of the perigastric nodes; D2, extended lymphadenectomy.
* Except for age in years and time since operation, which are expressed as mean ± standard deviation.BMC Health Services Research 2009, 9:133 http://www.biomedcentral.com/1472-6963/9/133
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Our findings are consistent with a previous Korean study,
which found that younger, highly educated, wealthier,
and employed patients were most likely to have PHI cov-
erage [21]. Similar findings have been reported in Taiwan,
where PHI serves a supplement to mandatory NHI cover-
age [22]. The Medigap plan, which provides supplemen-
tary insurance to Medicare beneficiaries in the US, is more
likely to be purchased by elderly patients who are rela-
tively younger, wealthier, better educated and in better
health [23]. Taken together, it is unlikely that supplemen-
tary PHI functions as an adequate safety net for vulnerable
populations.
Interestingly, most cancer survivors expressed apprecia-
tion for the assistance provided by supplementary PHI
coverage. This result should be interpreted with caution,
as these subjects are the winners of "jackpot" insurance. It
has been suggested that supplementary PHI is likely to
over-insure (and occasionally underinsure) Korean
patients. The average benefits awarded to newly diag-
nosed cancer patients between 2001 and 2005 were
approximately $20,000 USD (i.e., 19 million KRW, with
an exchange rate of 900 to 1000 during that period) [24],
while co-payments during the year of diagnosis are often
lower than $10,000 USD. This may explain why many
cancer survivors perceive PHI as beneficial, and why they
are more likely than other patients to pay their own med-
ical bills.
Our findings indicate that, apart from financial independ-
ence, PHI does not significantly impact access to health
care, patient autonomy or patient satisfaction. Thus,
patients with PHI appear to receive similar treatment as
those without PHI. This is in contrast to other studies,
which have suggested that PHI improves healthcare acces-
sibility [16,25] and influences quality of care [26].
Our finding that PHI has no significant beneficial influ-
ence on cancer care is somewhat disappointing, because
previous studies have consistently shown that PHI
Table 2: Determinants of having supplementary private health insurance.
PHI Status*
No PHI
(N = 190), %
PHI
(N = 187), %
Univariate OR(95% C.I.) Adjusted OR**(95% C.I.)
Age at diagnosis
> 51 years 154 (67.2) 75 (32.8)
≤ 50 years 36 (24.3) 112 (75.7) 6.39 (4.00 – 10.18) 5.01 (2.05 – 12.24)
Martial Status
Unmarried 25 (55.6) 20 (44.4)
Married 161 (49.5) 164 (50.5) 1.27 (0.68 – 2.38) 0.51 (0.15–1.71)
Education
Middle school or below 102 (65.8) 53 (34.2)
High school or beyond 83 (38.4) 133 (61.6) 3.08 (2.01 – 4.74) 2.67 (1.04 – 6.86)
Employment at diagnosis
No 83 (66.4) 42 (33.6)
Yes 100 (41.0) 144 (59.0) 2.85 (1.81 – 4.46) 2.76 (0.91 – 8.33)
Religion
No religion 65 (58.0) 47 (42.0)
Having a religion 123 (46.8) 140 (53.2) 1.57 (1.01 – 2.46) 2.30 (0.91 – 5.83)
Monthly household income
< $2,200 USD 88 (66.7) 44 (33.3)
> $2,200 USD 69 (36.1) 122 (63.9) 3.54 (2.22 – 5.64) 2.21 (0.87 – 5.60)
Comorbidity
Yes 77 (53.4) 67 (46.5)
No 113 (48.5) 120 (51.5) 1.22 (0.81 – 1.85) 0.65 (0.26 – 1.62)
Smoking at diagnosis
Yes 80 (47.6) 88 (52.3)
No 78 (51.7) 73 (48.3) 0.85 (0.55 – 1.32) 1.19 (0.46 – 3.04)
Alcohol at diagnosis
Yes 101 (49.0) 105 (51.0)
No 56 (52.8) 50 (47.2) 0.86 (0.54 – 1.37) 1.91 (0.71 – 5.12)
Residential area
Rural 57 (64.0) 32 (36.0)
Urban 131 (46.1) 153 (53.9) 2.08 (1.27 – 3.40) 2.41 (0.68 – 8.49)
*Among a total of 391 respondents, 14 failed to indicate whether they had private health insurance.
**Standard multivariate logistic regression was performed using all the variables in univariate analysis.BMC Health Services Research 2009, 9:133 http://www.biomedcentral.com/1472-6963/9/133
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Table 3: Impact of supplementary private health insurance on various aspects of the cancer care experience.
Univariate OR(95% C.I.) Adjusted OR(95% C.I.)
Access to healthcare
Stage at Diagnosis
II – IIIb Ia – Ib
No PHI 61 (32.3) 128 (67.7)
Having PHI 48 (25.8) 138 (73.8) 1.37 (0.86 – 2.15) 1.66 (0.93 – 2.99)
Difficulty receiving surgery
No Yes
No PHI 113 (61.4) 71 (38.6)
Having PHI 115 (62.8) 68 (37.2) 0.94 (0.62 – 1.44) 1.09 (0.59 – 1.74)
Quality of cancer care
Treatment according to guidelines
No Yes
No PHI 28 (15.2) 156 (84.8)
Having PHI 16 (8.8) 165 (91.2) 1.85 (0.96 – 3.55) 2.43 (0.98 – 6.04)
Overall satisfaction with care
No Yes
No PHI 28 (15.1) 157 (84.9)
Having PHI 28 (15.1) 157 (84.9) 1.00 (0.57 – 1.77) 1.21 (0.58 – 2.52)
Communication & patient autonomy
Involvement in decision making
No Yes
No PHI 71 (38.8) 112 (61.2)
Having PHI 79 (42.7) 106 (57.3) 0.85 (0.56 – 1.29) 0.77 (0.45 – 1.30)
Reflection of own opinion in decision
No Yes
No PHI 124 (67.8) 59 (32.2)
Having PHI 121 (66.5) 61 (33.5) 1.06 (0.69 – 1.64) 1.03 (0.59 – 1.79)
Financial & social independence
Payment of treatment costs by oneself
No Yes
No PHI 109 (57.4) 59 (31.6)
Having PHI 81 (42.6) 128 (68.4) 2.92 (1.92 – 4.45) 2.07 (1.19 – 3.61)
Job maintenance after cancer treatment
No Yes
No PHI 29 (29.3) 70 (70.7)
Having PHI 26 (18.3) 116 (81.7) 1.85 (1.01 – 3.39) 0.93 (0.43 – 1.99)
* Adjusted by standard logistic regression for possible confounding variables (e.g., age at diagnosis, educational status, religion, income, residential 
area, and employment status at the time of diagnosis).
** N = 253, having a job at the time of diagnosis.BMC Health Services Research 2009, 9:133 http://www.biomedcentral.com/1472-6963/9/133
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increases the utilization and expenditure of healthcare in
Korea. Those previous data are indicative of insurance
effects or moral hazards, at least in outpatient settings
[24,27,28]. However, our findings are not surprising
when the mechanisms of PHI in Korea are examined more
closely. Unlike PHI companies in the US, which provide
primary coverage for most of the population and reim-
burse patients for incurred expenses, PHI companies in
Korea do not have access to medical data, and cannot
impose regulations on patient care (e.g., with regards to
healthcare access, service coverage and quality of care).
Thus, our results suggest that expanding PHI coverage will
not improve the Korean health care system.
Our study has several limitations. By conducting a retro-
spective, cross-sectional survey of disease-free survivors of
stomach cancer, our results are subject to recall bias and
we were unable to assess the patients' experiences during
the actual treatment period. Also, patients with advanced
disease or recurrence were not included in our analysis,
which may have contributed to the relatively high satisfac-
tion rate. Furthermore, a potential selection bias may have
resulted from our low response rate (i.e., 52.8%). How-
ever, adjustment via the propensity weighting method
[29] showed no significant differences from our original
findings (data not shown), suggesting that the respond-
ents adequately represented the entire eligible popula-
tion. Last, as these data were obtained from a general
cancer survivorship survey, we were unable to determine
specific details regarding patients' PHI coverage, such as
the type of plans and the amount of benefits. However,
due to the unique characteristics of PHI in Korea, these
data were not required for the interpretation of our
results.
Conclusion
Our findings provide valuable lessons for developing
countries aiming to achieve universal healthcare coverage
in a short time. Policymakers might be easily tempted to
promote supplementary PHI to relieve government bur-
dens, assuming PHI will exert a beneficial effect on health-
care performance. However, our findings demonstrate
that supplementary PHI neither serves as a safety net for
vulnerable patients nor improves cancer care, except for
maintaining the financial independence of beneficiaries.
Cancer insurance worsened the financial stability of PHI
companies, halting sales in 2006 [30], and development
of diverse PHI plans has been underway since the Korean
government allowed indemnity-type health insurance in
2005. Future studies are needed to determine how new
private-public interactions might affect healthcare per-
formance in Korea.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DWS, KTJ, YHY designed the study. SK, JMB, YWK, KWR,
JHL, JHN, STS collected the data. DWS wrote the first
draft, which was revised by KTJ and YHY. All authors have
read and approved the final manuscript.
Additional material
Acknowledgements
This work was supported by National Cancer Center Grants 04101502 and 
0710731-3.
References
1. Fan M: Health Care Tops List Of Concerns in China.  Washing-
ton Post 2008.
2. Lancet:  China unveils plans for health-care reform.  Lancet
2008, 372:1608.
3. Tang S, Meng Q, Chen L, Bekedam H, Evans T, Whitehead M: Tack-
ling the challenges to health equity in China.  Lancet 2008,
372:1493-1501.
4. Hu S, Tang S, Liu Y, Zhao Y, Escobar ML, de Ferranti D: Reform of
how health care is paid for in China: challenges and opportu-
nities.  Lancet 2008, 372:1846-1853.
5. Chen T, Ye X: Private Health Insurance and Health Actuary in
Mainland China.  Proceedings of the 14th East Asian Actuarial Confer-
ence: Tokyo 2007.
6. Kwon S: Thirty years of national health insurance in South
Korea: lessons for achieving universal health care coverage.
Health policy and planning 2009, 24:63-71.
7. National Health Insurance Program in Korea 2001   [http://
www.mohw.go.kr]
8. Peabody JW, Lee SW, Bickel SR: Health for all in the Republic of
Korea: one country's experience with implementing univer-
sal health care.  Health policy (Amsterdam, Netherlands) 1995,
31:29-42.
9. Lee JC: Health care reform in South Korea: success or failure?
American journal of public health 2003, 93:48-51.
10. Organisation for Economic Co-operation and Development: OECD
Health Data 2006.  Paris 2006.
11. Kim JH, Jung JC: The Survey on out-of-pocket expenditure in
the insured of NHS in Korea.  National Health Insurance Forum
2005, 4:74-88.
12. Seo NK: The National Survey on Satisfaction with National
Health Insurance in 2004.  Health Insurance Forum 2005, 4:61-73.
13. Yoon T-H, Hwang I-K, Soh H-S, Koh K-W, Jeong B-G: The Deter-
minants of private health insurance purchasing decisions
under national health insurance systems in Korea: The
expanding of private health insurance market, for the better
or worse.  Korean J of Health Policy & Administration 2005, 15:161-175.
14. Korea Insurance Development Institute: Risk Management of Pri-
vate Health Insurance, CEO Report.  Seoul 2005.
15. Lee J-S: Industrialization of health care service and National
Health Insurance.  National Health Insurance Forum 2005, 4:5-16.
16. Chen AY, Schrag NM, Halpern MT, Ward EM: The impact of
health insurance status on stage at diagnosis of oropharyn-
geal cancer.  Cancer 2007, 110:395-402.
17. Shin J, Moon S: Quality of care and role of health insurance
among non-elderly women with disabilities.  Womens Health
Issues 2008, 18:238-248.
18. Korea Central Cancer Registry & Ministry of Health and Welfare:
2002 Annual Report of the Korea Central Cancer Regis-
Additional file 1
Appendix. Items used in the questionnaire and operational definitions.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-9-133-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Health Services Research 2009, 9:133 http://www.biomedcentral.com/1472-6963/9/133
Page 8 of 8
(page number not for citation purposes)
try(Based on Registered Data from 139 Hospitals).  Seoul
2003.
19. Bae JM, Kim S, Kim YW, Ryu KW, Lee JH, Noh JH, Sohn TS, Hong
SK, Park SM, You CH, Kim JH, Lee MK, Yun YH: Health-related
quality of life among disease-free stomach cancer survivors
in Korea.  Qual Life Res 2006, 15:1587-1596.
20. Noh SH, Lee J-I: Gastric Cancer Practice Guideline.  Journal of
Korean Gastric Cancer Association 2004, 4:286-293.
21. Lim JH, Kim SG, Lee EM, Bae SY, Park JH, Hahm M-I, Park E-C: The
Determinants of Purchasing Private Health Insurance in
Korean Cancer Patients.  J Prev Med Public Health 2007,
40:150-154.
22. Liu TC, Chen CS: An analysis of private health insurance pur-
chasing decisions with national health insurance in Taiwan.
Social science & medicine 2002, 55:755-774.
23. Ettner SL: Adverse selection and the purchase of Medigap
insurance by the elderly.  Journal of health economics 1997,
16:543-562.
24. Lim JH, Choi KS, Kim SG, Park E-C, Park JH: Effects of Private
Health Insurance on Health care Utilization and Expendi-
tures in Korean Cancer Patients: Focused on 5 Major Can-
cers in One Cancer Center.  J Prev Med Public Health 2007,
40:197-204.
25. Siciliani L, Hurst J: Tackling excessive waiting times for elective
surgery: a comparative analysis of policies in 12 OECD coun-
tries.  Health policy (Amsterdam, Netherlands) 2005, 72:201-215.
26. Kelz RR, Gimotty PA, Polsky D, Norman S, Fraker D, DeMichele A:
Morbidity and mortality of colorectal carcinoma surgery dif-
fers by insurance status.  Cancer 2004, 101:2187-2194.
27. Kang SW, Kwon YD, You CH: Effects of supplemental insurance
on health care utilization and expenditures among cancer
patients in Korea.  Korean J Health Policy Admin 2005, 15:65-80.
28. Jung KT, Shin EK, Kwak CH: An Empirical Study on the Rela-
tionship between Private Health Insurance and Moral Haz-
ard.  Korean Insur J 2006, 75:1-25.
29. Jenkins P, Earle-Richardson G, Burdick P, May J: Handling nonre-
sponse in surveys: analytic corrections compared with con-
verting nonresponders.  American journal of epidemiology 2008,
167:369-374.
30. Financial Supervisory Service: Press Release: Current situation of
Cancer Insurance Sales and the Direction of Regulation.
Seoul 2006.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6963/9/133/pre
pub